Madrigal Pharmaceuticals, Inc. MDGL
400.43 USD +4.11 (+1.04%)
At closeNov 5, 2026, 6:09 AM EST
402.46 +2.03 +0.51%
Pre-market · Nov 5, 6:09 AM ET
353.54 Day range 402.48
353.54 52-week range 615.00
- YTD
- -31.24%
- 1 year
- -9.94%
- Market cap
- 9.30B
- Revenue (ttm)
- 1.43B
- Profit margin
- -10.89%
- EPS (ttm)
- -5.85
- Shares out
- 23.23M
- Forward P/E
- 41.60
- YTD return
- -31.24%
- 1-year return
- -9.94%
- Volume
- 2.31M
- Avg volume
- 294.50K
- Open
- 398.89
- Previous close
- 396.32
- Day's range
- 353.54 – 402.48
- 52-week range
- 353.54 – 615.00
- Analysts
- Strong Buy
- Price target
- 686.06 (+71.3%)
- Earnings date
- Feb 18, 2027
5D -38.27 (-8.72%)
Key statistics
- Enterprise value
- 8.13B
- PEG ratio
- 0.00
- Price / sales
- 6.51
- Price / book
- 14.75
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 50.10%
- Free cash flow
- 0
- Total cash
- 961.77M
- Total debt
- 0
- Return on equity
- -24.82%
- Short % of float
- 11.10%
- 50-day average
- 494.64
- 200-day average
- 499.10
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 686.06 +71.3% upside
Now 400.43
- Target (low)
- 479.00
- Target (mean)
- 686.06
- Target (high)
- 962.00
Ratings (0m) 19 18 buy · 1 hold · 0 sell
- Strong buy3
- Buy15
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 18, 2027
Expected Feb 18, 2027. Consensus EPS estimate -0.4225.
Financials — quick view
MDGL Revenue — quarterly 431.27M
MDGL Net income — quarterly 55.44M
MDGL EPS — quarterly 1.90
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 18, 2027 | Dec 30, 2026 | -0.57 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | -0.86315 | 1.83 | +2.69 | +312.01% |
| Jul 30, 2026 | Jun 30, 2026 | -2.68 | -1.99 | +0.69 | +25.75% |
| May 6, 2026 | Mar 31, 2026 | -3.61 | -3.25 | +0.36 | +9.97% |
| Feb 19, 2026 | Dec 31, 2025 | 0.04 | -2.57 | -2.61 | -6,525.00% |
| Nov 4, 2025 | Sep 30, 2025 | -2.04 | -5.08 | -3.04 | -149.38% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | Truist Securities | reit | Buy | Buy |
| Nov 3, 2026 | Citigroup | main | Buy | Buy |
| Sep 23, 2026 | Citigroup | init | — | Buy |
| Aug 4, 2026 | Wolfe Research | up | Peer Perform | Outperform |
| Aug 3, 2026 | Barclays | main | Overweight | Overweight |
| Jul 29, 2026 | Canaccord Genuity | main | Buy | Buy |
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- madrigalpharma.com
News
Canaccord Genuity Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $633 
MADRIGAL PHARMACEUTICALS, INC. INVESTIGATION: MDGL Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights 
Truist Securities Reiterates Buy on Madrigal Pharmaceuticals, Raises Price Target to $743 
Kaplan Fox & Kilsheimer LLP Encourages Madrigal Pharmaceuticals, Inc. (MDGL) Investors to Contact the Firm Regarding Potential Securities Law Violations 
Madrigal Q3 Earnings: Why I'm Upgrading The Stock Again In 2026, This Time To Buy 
Madrigal Pharmaceuticals, Inc. (MDGL) Q3 2026 Earnings Call Transcript 
Citigroup Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $760 
What Madrigal Pharmaceuticals (MDGL) Said on Its Q3 Earnings Call 
Madrigal Pharmaceuticals Q3 2026 Earnings Call Transcript 
Madrigal (MDGL) Q3 Earnings and Revenues Beat Estimates
Your note
Sign in to keep a note on MDGL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS, L.P. | Unknown | Stock Award(Grant) | Jun 16, 2026 | 0 |
| CRAVES FREDERICK B | Director | Sale | Mar 12, 2025 | 383,547 |
| DIER MARDI C | Chief Financial Officer | Sale | Mar 5, 2026 | 12,490 |
| FRIEDMAN PAUL A | Director | Sale | Jan 8, 2026 | 842,704 |
| HUNTSMAN CAROLE A | Officer | Sale | Mar 5, 2026 | 12,692 |
| KELLEY SHANNON T | General Counsel | Sale | Aug 16, 2026 | 11,474 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 9.28% | 2,143,131 | 858.17M | Jun 29, 2026 |
| RTW Investments LP | 8.63% | 1,993,687 | 798.33M | Jun 29, 2026 |
| Jupiter Topco LLC | 8.38% | 1,936,099 | 775.27M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 7.94% | 1,833,333 | 734.12M | Jun 29, 2026 |
| PAULSON & CO. INC. | 5.80% | 1,340,020 | 536.58M | Jun 29, 2026 |
| Blackrock Inc. | 5.20% | 1,200,770 | 480.82M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.53% | 584,997 | 234.25M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.44% | 563,117 | 225.49M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.83% | 423,142 | 169.44M | Jun 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Forty Fund | 1.47% | 338,602 | 135.59M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.17% | 270,288 | 108.23M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.05% | 243,683 | 97.58M | Jun 29, 2026 |